Half-Year 2022 Financial and Clinical Trials Update
Roche
SMA franchise: Evrysdi with strong global momentum
US with >20% and Germany with >30% share
CHFM
300
250
200
>500%
150
100
50
50
+347%
Q2 update
•
YoY CER growth
+65%
•
+189%
0
Q3 20
Q4 20
Q1 21
Q2 21
Q3 21
Q4 21
Q122
Q2 22
US
Europe International
Japan
.
>5,000 patients treated world wide (commercial, clinical
trials, compassionate use)
Retention rate of ~90% due to treatment satisfaction
US: Growth driven by switch and naive patient starts; US
approval for patients <2 months old achieved.
• EU: Strong launches in early launch countries
•
Ph II/III (MANATEE) Evrysdi + anti-myostatin combination
study started
Outlook 2022
•
Continued growth and market share gains over all market
segments expected
• EU: Label extension (<2 months old) based on Ph II
CER-Constant Exchange Rates; SMA-spinal muscular atrophy; Anti-myostatin (GYM329) in collaboration with Chugai
RAINBOWFISH expected
29View entire presentation